Claims for Patent: 7,300,674

Summary for Patent: 7,300,674

Title:	Sterile low bicarbonate dialysis concentrate solutions
Abstract:	The present invention relates to a sterile calcium-free low bicarbonate dialysis concentrate composition for use in conjunction with regional citrate anti-coagulation in the context of either dialysis or hemofiltration. Methods of use of the sterile calcium free low bicarbonate dialysis concentrate compositions are also disclosed. The low bicarbonate concentrate takes into account the fact that citrate is hepatically metabolized into bicarbonate, thus minimizing metabolic complications.
Inventor(s):	Tobe; Sheldon (Toronto, Ontario, CA)
Assignee:
Application Number:	10/020,882
Patent Claims:	1. A sterile calcium free low bicarbonate dialysis concentrate composition containing sodium chloride, magnesium chloride and sodium bicarbonate for continuous renal replacement therapy and for use in the preparation of a sterile calcium free dialysis solution comprising sodium chloride (NaCl), magnesium chloride (MgCl.sub.2), and a concentration of sodium bicarbonate (NaHCO.sub.3) sufficiently low so as to allow preparation of the sterile calcium free dialysis solution for continuous renal replacement therapy, having ion concentrations of Na 140.+-.14 mmol/l, Mg 0.75.+-.0.07 mmol/l, Cl 116.5.+-.11 mmol/l, and HCO.sub.3 25.0.+-.2.5 mmol/l. 2. A sterile calcium free low bicarbonate dialysis concentrate composition containing sodium chloride, magnesium chloride and sodium bicarbonate for continuous renal replacement therapy and for use in the preparation of a sterile calcium free dialysis solution comprising sodium chloride (NaCl), magnesium chloride (MgCl.sub.2), and a concentration of sodium bicarbonate (NaHCO.sub.3) sufficiently low so as to allow preparation of the sterile calcium free dialysis solution for continuous renal replacement therapy, having ion concentrations of Na 140.+-.14 mmol/l, Mg 0.75.+-.0.07 mmol/l, 01116.5.+-.11 mmol/l, and HCO.sub.3 of from 20 to less than 30 mmol/l. 3. A kit for preparing a sterile calcium free dialysis solution comprising the sterile calcium free dialysis concentrate composition of claim 1 or 2 and optionally instructions for use. 4. The kit of claim 3, further comprising sterile water sufficient to dilute the concentrate to a sterile calcium free dialysis solution comprising Na 140.+-.14 mmol/l, Mg 0.75.+-.0.07 mmol/l, Cl 116.5.+-.11 mmol/l, and HCO.sub.3 25.0.+-.2.5 mmol/l. 5. A method of preparing a sterile calcium free dialysis solution comprising diluting a sterile calcium free dialysis concentrate composition of claim 1 or 2 in a sufficient amount of sterile water to prepare a sterile calcium free dialysis solution comprising Na .140.+-.14 mmol/l, Mg 0.75.+-.0.07 mmol/l, Cl 116.5.+-.11 mmol/l, and HCO.sub.3 25.0.+-.2.5 mmol/l. 6. A method for providing continuous renal replacement therapy to a patient comprising administering a sterile calcium free dialysis solution prepared according to the method of claim 5 in conjunction with a regional citrate anti-coagulant solution to a patient in need thereof. 7. A method of preparing a sterile calcium free dialysis solution or infusate comprising diluting a sterile calcium free dialysis concentrate composition of claim 1 or 2 in a sufficient amount of sterile water to prepare a sterile calcium free dialysis solution or infusate comprising Na 140.+-.14 mmol/l, Mg 0.75.+-.0.07 mmol/l, Cl 116.5.+-.11 mmol/l, and HCO.sub.3 25.0.+-.2.5 mmol/l. 8. A method for treating acute renal failure in a critically ill patient without introducing calcium into the blood removed from the patient during dialysis comprising administering a sterile calcium free dialysis solution prepared according to the method of claim 7 in conjunction with a regional citrate anti-coagulant solution to a patient in need thereof. 9. A method for providing hemofiltration to a patient comprising administering a sterile calcium free infusate prepared according to the method of claim 7 in conjunction with a regional citrate anti-coagulant solution to a patient in need thereof.

Details for Patent 7,300,674

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2020-12-20